DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Integrated RF and B-mode Deformation Analysis for 4D Stress Echocardiography

Information source: Yale University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Coronary Artery Disease

Intervention: Stress Dobutamine Echocardiographic using 4DE System (Procedure)

Phase: N/A

Status: Not yet recruiting

Sponsored by: Yale University

Official(s) and/or principal investigator(s):
Albert Sinusas, MD, Principal Investigator, Affiliation: Yale University

Overall contact:
Donna McMahon, Phone: 203-785-5005, Email: donna.mcmahon@yale.edu

Summary

The specific aim of this clinical trial is to translate the investigators new 4DE (three sptial dimensions pluse time) stress echocardiographic method to patients with coronary artery disease referred for clinically indicated dobutamine stress/rest echo to evaluate the reproducibility of the technique in this clinical setting.

Clinical Details

Official title: Integrated RF and B-mode Deformation Analysis for 4D Stress Echocardiography

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Primary outcome: Number of Subjects With an Interpretable 4DE Image

Eligibility

Minimum age: 18 Years. Maximum age: 90 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- At least 18 years of age, referred for clinically indicated dobutamine rest/stress

TTE

- Provide written informed consent to participate in the study

- Availability for repease rest/stress TTE within on eweek of clinically indicated

study Exclusion Criteria:

- Unable to give informed consent

- Unstable hemodynamics that would not allow for repease rest/stress dobutamine

transthoracic imaging

- Recurrent life threatening arrhythmias

- Heart rate >110 BPM

- Inadequate windows for transthoracic imagine

- Patients that have a narrow-angle glaucoma (contraindication for atropine)

- Change in cardiac medications or management including, coronary revascularization

beween intial and repeat TTE study.

Locations and Contacts

Donna McMahon, Phone: 203-785-5005, Email: donna.mcmahon@yale.edu

Additional Information

Starting date: January 2016
Last updated: December 22, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017